---
title: "Scilex Holding (SCLX) news: going concern and merger"
url: "https://aibio.space/companies/scilex/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "SCLX going concern and merger news: Scilex files NT 10-Q late filing notice, expects first quarter 10-Q by May 20, 2026."
---

SCLX Scilex Holding Company NASDAQ · United States

# Scilex Holding (SCLX) news SCLX going concern and merger news

Legal · 2026-08-14

## [Scilex loses ZTlido patent appeal as Federal Circuit affirms non-infringement ruling for Aveva](https://aibio.space/news/scilex-loses-ztlido-patent-appeal-federal-circuit-affirms-non/)

The Federal Circuit affirmed on Aug. 4, 2026 that Aveva's generic does not infringe Scilex's ZTlido patents. Defendants were Aveva Drug Delivery Systems, Apotex Corp. and Apotex, Inc.

## Latest Scilex Holding news

1. 2026-08-14 Legal [Scilex and Semnur named in Sorrento equity holders' suit, now stayed in a California federal court](https://aibio.space/news/scilex-semnur-named-sorrento-equity-holders-suit-now-stayed-california/) Mevi et al. v. Ji et al. names Scilex, Semnur and others not listed in the 10-Q. The court stayed the case on June 25, 2026; Scilex's filings do not identify the other defendants.
2. 2026-05-15 Distress [Scilex files NT 10-Q late filing notice, expects first quarter 10-Q by May 20, 2026](https://aibio.space/news/scilex-files-nt-10-q-late-filing-notice-expects-first-quarter-10-q-may/) Scilex Holding Company says it needs more time to finish its first-quarter 2026 financial statements, including the consolidation of Vivasor Holding Company, and expects to file by May 20, 2026. Its 2025 annual report carries a going-concern warning and an accumulated deficit of about $921.8 million.
3. 2026-04-01 Distress [Scilex files NT 10-K, needs more time for financial statements including Vivasor consolidation](https://aibio.space/news/scilex-files-nt-10-k-needs-more-time-financial-statements-including/) Scilex Holding Company says it could not file its annual report by the March 31, 2026 due date and expects to file by April 15, 2026. It says it needs more time to finalize financial statements, including consolidating Vivasor Holding Company.
4. 2025-04-30 Listings [Scilex Holding regains compliance with Nasdaq minimum bid price rule](https://aibio.space/news/scilex-holding-regains-compliance-nasdaq-minimum-bid-price-rule/) Scilex met the $1.00 minimum closing bid price requirement on April 30, 2025. Its common stock and public warrants stay on the Nasdaq Capital Market.
5. 2025-04-21 Mergers [Scilex unit Semnur amends Denali merger deal, moves outside date to September 30, 2025](https://aibio.space/news/scilex-unit-semnur-amends-denali-merger-deal-moves-outside-date/) Semnur signed Amendment No. 1 on April 16, 2025, covering Denali's move from Nasdaq to OTC quotation and extending its deadlines.
6. 2024-11-22 Financings [Scilex noteholders waive defaults tied to late third quarter report](https://aibio.space/news/scilex-noteholders-waive-defaults-tied-late-third-quarter-report/) Oramed and the Tranche B holders waived the missed quarterly filing on November 21, 2024. Scilex must deliver its September 2024 financial statements by January 20, 2025, through a new independent auditor.
7. 2024-11-14 Distress [Scilex Holding delays third-quarter 10-Q, notice cites an ongoing review](https://aibio.space/news/scilex-holding-delays-third-quarter-10-q-notice-cites-ongoing-review/) The company missed the November 14, 2024 due date for its report on the quarter ended September 30, 2024. The notice warns that an ongoing review may identify errors or control deficiencies in its accounting practices.

## Scilex Holding at a glance

- **Ticker**: SCLX

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $566,000

### Related companies

- [Nutra Pharma](https://aibio.space/companies/nutra-pharma/) OTC: NPHC
- [MIRA Pharmaceuticals](https://aibio.space/companies/mira-pharmaceuticals/) NASDAQ: MIRA
- [PharmaCyte Biotech](https://aibio.space/companies/pharmacyte-biotech/) NASDAQ: PMCB
- [IMMUNOTECH LABORATORIES INC](https://aibio.space/companies/immunotech-laboratories/) OTC: IMMB
- [Curanex Pharmaceuticals](https://aibio.space/companies/curanex-pharmaceuticals/) NASDAQ: CURX
- [Enveric Biosciences](https://aibio.space/companies/enveric-biosciences/) NASDAQ: ENVB
- [Earth Science Tech](https://aibio.space/companies/earth-science-tech/) OTC: ETST
- [iBio](https://aibio.space/companies/ibio/) NASDAQ: IBIO

### Also on NASDAQ

- [Liminatus Pharma](https://aibio.space/companies/liminatus-pharma/) LIMN
- [Fractyl Health](https://aibio.space/companies/fractyl-health/) GUTS
- [Larimar Therapeutics](https://aibio.space/companies/larimar-therapeutics/) LRMR
- [Halozyme Therapeutics](https://aibio.space/companies/halozyme-therapeutics/) HALO
- [Vericel](https://aibio.space/companies/vericel/) VCEL
- [NeOnc Technologies Holdings](https://aibio.space/companies/neonc-technologies/) NTHI

## What Scilex Holding does

Scilex Holding Company is a revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for acute and chronic pain. Its three commercial products are ZTlido, a prescription lidocaine topical system for neuropathic pain from postherpetic neuralgia; ELYXYB, a ready-to-use oral celecoxib solution for acute migraine in adults; and GLOPERBA, a liquid oral colchicine for prophylaxis of painful gout flares in adults. ZTlido is manufactured in Japan by Oishi Koseido Co., Ltd., and the company relies on Oishi and Itochu Chemical Frontier Corporation for it. GLOPERBA rights come from a license with RxOmeg Therapeutics LLC, also called Romeg. Its candidates include SP-102 (SEMDEXA), a viscous gel corticosteroid for epidural injection in sciatica; SP-103, a triple-strength lidocaine topical system for acute low back pain; and SP-104, a low-dose delayed-release naltrexone for fibromyalgia. The text also describes a cryptocurrency treasury strategy under which the company intends to invest in bitcoin, Ethereum and other blockchain-linked cryptocurrencies.

| Product or program | What it is | Stage |
|---|---|---|
| ZTlido | Prescription lidocaine topical system for postherpetic neuralgia pain | FDA-approved; commercial product |
| ELYXYB | Ready-to-use oral celecoxib solution for acute migraine in adults | FDA-approved; commercial product |
| GLOPERBA | Liquid oral colchicine for prophylaxis of painful gout flares in adults | FDA-approved; launched June 2024 |
| SP-102 (SEMDEXA) | Viscous gel corticosteroid for epidural injection to treat sciatica | Phase 3 study completed |
| SP-103 | Triple-strength lidocaine topical system for acute low back pain | Phase 2 trial completed |
| SP-104 | Low-dose delayed-release naltrexone for fibromyalgia | Phase 1 trials completed |

Summarised from the company's [10-K filed Apr 10, 2026](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/sclx-20251231.htm).

## Scilex Holding annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$30.3 million](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/) | [$56.6 million](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/) |
| Research and development | [$20.7 million](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/) | [$9.6 million](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/) |
| Net income (loss) | [-$374.1 million](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/) | [-$72.8 million](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/) |
| Cash from operations | [$3.8 million](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/) | [$19.3 million](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/) |
| Cash and equivalents | [$5.0 million](https://www.sec.gov/Archives/edgar/data/1820190/000119312526352464/) | [$3.3 million](https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $566,000.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Scilex Holding

Has Scilex Holding issued a going-concern warning?

Our latest story on this, dated May 15, 2026: "Scilex files NT 10-Q late filing notice, expects first quarter 10-Q by May 20, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/scilex-files-nt-10-q-late-filing-notice-expects-first-quarter-10-q-may/).

Is Scilex Holding involved in a merger or acquisition?

Our latest story on this, dated Apr 21, 2025: "Scilex unit Semnur amends Denali merger deal, moves outside date to September 30, 2025". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/scilex-unit-semnur-amends-denali-merger-deal-moves-outside-date/).

What is the ticker symbol of Scilex Holding?

Scilex Holding Company trades under the ticker SCLX on NASDAQ.

Where is Scilex Holding listed?

Scilex Holding Company is listed on NASDAQ.

What is the SEC CIK of Scilex Holding?

The SEC Central Index Key (CIK) for Scilex Holding Company is 1820190. Its filings are on SEC EDGAR.

How many shares does Scilex Holding have outstanding?

8,493,000 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is Scilex Holding listed under?

Our directory records Scilex Holding Company under United States.

What does Scilex Holding do?

Our directory classifies Scilex Holding Company as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.

What is the ISIN of Scilex Holding?

The ISIN recorded for Scilex Holding Company is US80880W2052.

Does aibio.space cover Scilex Holding?

aibio.space lists Scilex Holding Company among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Scilex Holding incorporated?

SEC records list its state or country of incorporation as DE.

What does Scilex Holding develop?

Scilex Holding Company is a revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for acute and chronic pain. Its three commercial products are ZTlido, a prescription lidocaine topical system for neuropathic pain from postherpetic neuralgia; ELYXYB, a ready-to-use oral celecoxib solution for acute migraine in adults; and GLOPERBA, a liquid oral colchicine for prophylaxis of painful gout flares in adults.

What is ZTlido from Scilex Holding?

ZTlido: Prescription lidocaine topical system for postherpetic neuralgia pain Stage: FDA-approved; commercial product.

What is ELYXYB from Scilex Holding?

ELYXYB: Ready-to-use oral celecoxib solution for acute migraine in adults Stage: FDA-approved; commercial product.

What was Scilex Holding's revenue last year?

$30.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

## Investor discussion: Scilex Holding

Members talk about Scilex Holding (SCLX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Scilex Holding, newest first. Each line links the filing it comes from.

1. 2026-07-22 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312526312591/sclx-20260718.htm)
2. 2026-06-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312526288677/sclx-20260624.htm)
3. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312526226675/scilex_nt_10q_2026.htm)
4. 2026-05-11 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312526216921/sclx-ex99_1.htm)
5. 2026-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312526135582/scilex_nt_10k_2025.htm)
6. 2026-02-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312526061371/sclx-20260219.htm)
7. 2025-12-16 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525319720/d948132ds1.htm)
8. 2025-12-01 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525303037/d26514dex991.htm)
9. 2025-10-31 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525259819/sclx-20251030.htm)
10. 2025-09-26 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525220446/sclx-ex99_1.htm)
11. 2025-08-04 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525172703/d942297ds1.htm)
12. 2025-07-23 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525162938/d87162d8k.htm)
13. 2025-04-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000095017025061130/sclx-ex99_1.htm)
14. 2025-04-21 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000095017025056022/sclx-20250416.htm)
15. 2025-04-15 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525080856/d943368d8k.htm)
16. 2025-04-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525078604/d836626dex991.htm)
17. 2025-03-20 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000095017025042708/sclx-20250319.htm)
18. 2025-03-03 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525043879/d812498d8k.htm)
19. 2025-02-27 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525039223/d869816ddef14a.htm)
20. 2025-02-14 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312525027244/d869816dpre14a.htm)
21. 2025-01-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000095017025007359/sclx-ex99_1.htm)
22. 2024-12-06 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000095017024133869/sclx-20241205.htm)
23. 2024-11-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312524263748/d901268dex991.htm)
24. 2024-11-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312524264187/d914468d8k.htm)
25. 2024-11-20 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312524262065/d874287d8k.htm)
26. 2024-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312524258692/d904641dnt10q.htm)
27. 2024-11-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312524253177/d857855d8k.htm)
28. 2024-11-06 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1820190/000119312524251872/d811406dex991.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SCLX on TradingView](https://www.tradingview.com/symbols/NASDAQ-SCLX/).

## SEC filings and registration

- **SEC name**: Scilex Holding Co

- **CIK**: 1820190

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: SCLX (Nasdaq), SCLXW (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: <br>Emerging growth company

- **Business address**: 960 SAN ANTONIO ROAD, PALO ALTO, CA, 94303

- **Phone**: (650) 516-4310

- **Shares outstanding**: 8,493,000 as of 2026-08-10 (10-Q filed 2026-08-14)

- **Former names**: Scilex Holding Company/DE; Vickers Vantage Corp. I

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1820190/000119312526407333/sclx-20260925.htm) filed 2026-09-29
- [10-Q](https://www.sec.gov/Archives/edgar/data/1820190/000119312526352464/sclx-20260630.htm) filed 2026-08-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1820190/000119312526347186/sclx-20260808.htm) filed 2026-08-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1820190/000119312526312591/sclx-20260718.htm) filed 2026-07-22
- [8-K](https://www.sec.gov/Archives/edgar/data/1820190/000119312526295493/sclx-20260703.htm) filed 2026-07-06
- [8-K](https://www.sec.gov/Archives/edgar/data/1820190/000119312526288677/sclx-20260624.htm) filed 2026-06-29
- [8-K](https://www.sec.gov/Archives/edgar/data/1820190/000119312526281213/sclx-20260624.htm) filed 2026-06-24
- [S-3](https://www.sec.gov/Archives/edgar/data/1820190/000119312526253831/d279959ds3.htm) filed 2026-06-02

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001820190), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Scilex Holding Company is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SCLX, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Scilex Holding Company

- **Ticker**: SCLX

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biopharma / pharmaceutical profile checked

- **ISIN**: US80880W2052

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SCLX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/scilex/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Scilex Holding (SCLX) news: going concern and merger", 2026-10-31, https://aibio.space/companies/scilex/